Parking...
SOUTH SAN FRANCISCO, CA, September 27, 1999 - Eos Biotechnology, Inc. today announced that the Company has completed a $27 million private placement of preferred stock.-The placement represents one of the largest private financings consummated in the biotechnology field in 1999.-Funds raised in this round of financing will be used to further develop the Company's genomics-based antibody therapeutics, initially against novel breast cancer targets.
Participants in the private placement included existing investors Bay City Capital, Venrock Associates, Rothschild BIL, TechnoVentures and Affymetrix, Inc. and new investors including Zesiger Capital Group, ProQuest Investments (an oncology-focused venture capital fund), Alfa-Tech, BancBoston Ventures, Charter Venture Capital, Sofinov and Vertical Group.
SOUTH SAN FRANCISCO, CA, September 28, 2000 - Eos Biotechnology, Inc. today announced the completion of a $27.5 million private placement of preferred stock. Funds raised in this round of financing will be used to further expand Eos' genomics-based technologies and databases, and to develop the Company's antibody therapeutics.
Participants in the private placement included existing investors and a number of new investors. Eos' corporate collaborators, Affymetrix, Biogen, and Medarex, participated in this investment round. U.S. Bancorp Piper Jaffray and Robertson Stephens were new investors. Following this financing, Eos' largest shareholders are Bay City Capital, ProQuest Investments, Venrock Associates, and Zesiger Capital Group. |
